Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.
Also called NCT02027753
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 109 participants
- Sponsor
- Registry
-
NCT02027753
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02027753. Allocation not applicable; no masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
- Acronym
- TED
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- INSULIN GLARGINE
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- DPP-4 inhibitor
- Intervention (Drug)
- Sulphonylurea
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02027753- Content hash
592edb5fca2406571005cc4cdc7553d48a83d3f8a1ddb2a0db884b67b32b4f6e